Key Stats for Pfizer Stock
- Current Price: $26.80
- Target Price (Mid): ~$29
- Street Target: ~$29
- Potential Total Return: ~9%
- Annualized IRR: ~2% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Pfizer (PFE) closed at $26.80 on August 13, and Albert Bourla, the company’s Chairman and CEO, is buying. On August 12, he purchased 38,000 shares on the open market at $26.34 apiece, a little over $1 million out of his own pocket, according to a Form 4 filed with the SEC. The trade is too small to move the stock on its own, and it did not: shares sit within pennies of what he paid. But a sitting CEO adding to a position he already holds, rather than taking a grant, is a deliberate signal, and for a name that has frustrated income investors for three years, it is the freshest reason to look again.
Shares yield 6.5%, trade at under 10 times next-twelve-months earnings, and just delivered a Q2 beat that lifted full-year revenue guidance. The catch is just as visible, and it is why the discount has persisted: the business is set to shrink before it grows, with a wall of patent expirations arriving in 2028.
The Beat Bourla Is Buying
Insider buying by a sitting CEO carries weight because Bourla is already paid heavily on performance, so adding $1 million on top is conviction rather than compensation. And Q2 gave him something to point to. Revenue came in at $15.03 billion, ahead of the $14.39 billion Street estimate, and adjusted EPS of $0.77 beat the $0.68 consensus.
Excluding COVID products, the underlying business grew 5% operationally, while launched and acquired products grew 18% operationally. Eliquis, the blood thinner co-marketed with Bristol Myers Squibb, rose 19% operationally on higher U.S. net price, and Padcev, the bladder-cancer therapy Pfizer markets with Astellas, grew 23% operationally after a July label expansion into muscle-invasive disease.
Management lifted the guidance midpoint by $500 million, to $60.5 billion to $62.5 billion, and announced $2.5 billion in additional savings for 2027 through 2029, bringing total expected net savings to $9.7 billion.
Interim CFO Cecile Guegan framed the raise as momentum, not a one-off. “The strength of our business led to the incremental $1.5 billion above the original guidance,” she said, crediting both the Q1 and Q2 non-COVID beats.
See historical and forward estimates for Pfizer stock (It’s free!) >>>
The Cliff That Isn’t Fixed Yet
Eliquis loses U.S. exclusivity around 2028, with settled generics able to launch soon after, and it is Pfizer’s largest franchise. RBC Capital’s Trung Huynh captured the market’s stance after the print, arguing Pfizer must deliver on key 2026 catalysts to be seen as a growth company again rather than a restructuring story. The GAAP loss of $0.04 sharpened the point: it stemmed from $4.3 billion in non-cash impairments, driven largely by the failed sigvotatug vedotin lung-cancer readout and the removal of Oxbryta projections. The pipeline is spending real money to find its next winner.
That is why Bourla’s most important words on the call were not about the pipeline. “We feel extremely confident that we will, even in the most stretched scenarios that we are running, we will be able to maintain our dividend,” he said. For a stock owned largely for its 6.5% dividend yield, that pledge is the load-bearing assumption, and it is not yet tested against the full force of the Eliquis cliff.
The discount reflects that unease. Pfizer trades near 9.7 times forward earnings against a peer group where Johnson & Johnson sits above 23 times and Novartis near 17 times; only Bristol Myers, which shares the Eliquis exposure, keeps it company near 10 times, per TIKR’s Competitors data. The market is pricing the two large caps whose patent cliffs look least offset by visible growth. The Street mostly agrees to wait: of the analysts covering the stock, 16 sit at Hold against 8 Buys, with a mean target near $29.
See how Pfizer performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $26.80
- Target Price (Mid): ~$29
- Potential Total Return: ~9%
- Annualized IRR: ~2% / year
See analysts’ growth forecasts and price targets for Pfizer stock (It’s free!) >>>
The mid case points to a target near $29, roughly 9% of total upside from today’s price, or about 2% annualized over the model’s horizon to 2030. That is deliberately the mid case, because it captures the stock’s tension: the return is real but thin, and almost none of it comes from the business growing.
The model assumes revenue growth stays slightly negative across the window, so the two levers are a net income margin holding in the mid-20s percent range on cost discipline, and a small re-rating off today’s depressed P/E. The margin driver is Pfizer’s $9.7 billion cost-savings program, carrying profitability while the top line contracts. The primary risk is the 2028 Eliquis cliff: if the pipeline does not begin replacing that revenue on schedule, both the margin assumption and the re-rating unwind together.
The upside is one blockbuster-scale pipeline win, whether the MEVPRO-1 prostate readout due in Q4 or the berobenatide obesity program, re-rating a stock priced for stagnation. The downside is a dividend that eats most of the return while the business shrinks, leaving holders waiting years for a recovery that arrives late.
Conclusion
The nearest test is MEVPRO-1, the Phase 3 prostate cancer trial for mevrometostat, with a first readout expected in Q4 2026. Management has said the study is powered to show a clinically meaningful benefit of roughly 30% over standard of care. A clear hit gives the market its first concrete reason to price Pfizer as more than a dividend-and-restructuring story, and validates the case Bourla just backed with his own money. A miss, or a muddy result, leaves the stock where it is: cheap, high-yielding, and waiting.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
